Trials and therapies in secondary progressive MS, simplified
Trials and therapies in secondary progressive MS, simplified
About this item
Full title
Trials and therapies in secondary progressive MS, simplified
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Nature reviews. Neurology, 2019-08, Vol.15 (8), p.431-432
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.
Alternative Titles
Full title
Trials and therapies in secondary progressive MS, simplified
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2254506849
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2254506849
Other Identifiers
ISSN
1759-4758
E-ISSN
1759-4766
DOI
10.1038/s41582-019-0233-x
